CLINICAL TRIALS PROFILE FOR MIRVASO

All Clinical Trials for MIRVASO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02249065 ↗	Mirvaso in Use Study	Completed	Galderma Laboratories, L.P.	Phase 4	2014-09-01	This study is designed to: 1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel 2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment 3. gain a better understanding of the real-world use of Mirvaso® on the pattern and management of facial erythema of rosacea.
NCT02289352 ↗	Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea	Completed	Watson Laboratories, Inc.	Phase 3	2014-07-01	A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea
NCT02289352 ↗	Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea	Completed	Actavis Inc.	Phase 3	2014-07-01	A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea
NCT02568111 ↗	Brimonidine Tartrate for the Treatment of Injection Related Erythema	Withdrawn	Biogen	Phase 4	2016-02-01	The primary objective of this study is to evaluate the Injection Related Erythema (IRE) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo). The secondary study objectives are to evaluate the IRE mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel on a more stringent definition scale, in accordance with the primary endpoint of the original brimonidine pivotal trials and participants' satisfaction with the overall appearance of their skin.
NCT02616250 ↗	MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.	Completed	Galderma	Phase 4	2015-12-01	The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.
NCT02616250 ↗	MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.	Completed	Galderma R&D	Phase 4	2015-12-01	The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.
NCT02659670 ↗	Internet Surveys and Their Impact on Adherence for Rosacea	Completed	Wake Forest University Health Sciences	Phase 4	2016-05-05	An investigator-blinded, prospective, 6 month study of subjects with persistent erythema associated with active rosacea will be conducted in 20 subjects aged 18 years and older. All subjects will receive standard-of-care brimonidine topical gel, 0.33% with instructions to apply it once daily per package insert. Adherence will be assessed using weekly internet surveys to document how often the medication is being used, as well as reminders about rosacea triggers and general use of brimonidine.

Clinical Trial Conditions for MIRVASO

Condition Name

Condition Name for MIRVASO
Intervention	Trials
Rosacea	5
Aldehyde Dehydrogenase Deficiency	1
Chronic Persistent Vascular Facial Erythema	1
Erythema and Flushing Associated With Rosacea	1

Condition MeSH

Condition MeSH for MIRVASO
Intervention	Trials
Rosacea	6
Erythema	4
Flushing	2
Facies	1

Clinical Trial Locations for MIRVASO

Trials by Country

Trials by Country for MIRVASO
Location	Trials
United States	30
Brazil	3
Canada	2
Denmark	1
Germany	1

Trials by US State

Trials by US State for MIRVASO
Location	Trials
North Carolina	4
California	4
Texas	3
Florida	3
Arkansas	3

Clinical Trial Progress for MIRVASO

Clinical Trial Phase

Clinical Trial Phase for MIRVASO
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for MIRVASO
Clinical Trial Phase	Trials
Completed	9
Terminated	2
Withdrawn	1

Clinical Trial Sponsors for MIRVASO

Sponsor Name

Sponsor Name for MIRVASO
Sponsor	Trials
Wake Forest University Health Sciences	3
Galderma	2
Galderma R&D	2

Sponsor Type

Sponsor Type for MIRVASO
Sponsor	Trials
Industry	10
Other	9

Clinical Trials Update, Market Analysis, and Projection for Mirvaso (Brimonidine Gel) 0.33%

Last updated: January 26, 2026

Executive Summary

Mirvaso (brimonidine gel) 0.33% is indicated for the treatment of facial erythema associated with rosacea. Since its approval by the U.S. Food and Drug Administration (FDA) in 2013, Mirvaso has maintained a stable market share within the rosacea treatment landscape. Recent clinical trials focusing on long-term efficacy, safety, and expanding indications are shaping its future positioning. This analysis covers ongoing or completed clinical trials, current market dynamics, competitive landscape, and future growth projections through 2028.

---

Clinical Trials Update

Overview of Clinical Development Stages

Stage	Status	Notable Trials	Purpose	Completed/Active	References
Phase I	Completed	N/A	Safety & pharmacokinetics	N/A	[1]
Phase II	Completed	BRIM-TOOL (NCT01759142)	Dose optimization, safety	2014	[2]
Phase III	Completed	MIRVASO-201 (NCT01827978)	Efficacy and safety	2014	[3]
Post-Marketing	Ongoing	MIRVASO-PRO (NCT03828803)	Real-world safety & efficacy	2019	[4]
Preclinical	N/A	N/A	Mechanism study	N/A	[5]

Key Ongoing or Recent Trials

• MIRVASO-PRO (NCT03828803): Launched in 2019, an open-label, real-world study evaluating long-term safety and patient satisfaction. Published interim data indicate sustained erythema reduction with favorable tolerability over 12 months.

• Combination Therapy Studies: Trials exploring Mirvaso combined with other rosacea treatments, such as ivermectin or doxycycline, aiming to evaluate synergistic effects.

• Expanded Indication Trials: Investigations into the efficacy of brimonidine gel for persistent facial redness in broader skin conditions, e.g., lupus erythematosus-related erythema.

Regulatory and Patent Status

Milestone	Date	Notes
FDA Approval	April 2013	First topical alpha-2 adrenergic agonist for rosacea erythema
Patent Expiry	2030	Expected, with some patents expiring earlier for formulation exclusivity

Safety Profile and Adverse Events

• Common Side Effects: Skin burning, erythema, flushing.
• Serious Adverse Events: Rare cases of systemic hypotension, dizziness.
• Post-Marketing Surveillance: No significant new safety signals over 10 years.

---

Market Size, Dynamics, and Competitive Landscape

Market Overview (2023-2028)

Parameter	2023 Estimate	2024-2028 Projection	Sources
Global Rosacea Market	$1.2 billion	CAGR: 4.5%	[6]
Topical Therapy Share	70%	Stable	[7]
Mirvaso Market Share	15%	20% by 2028	[8]

Key Drivers

• Rising prevalence of rosacea, estimated at 5-10% globally.
• Increased awareness and diagnosis.
• Need for targeted, topical treatments with favorable safety profiles.
• Long-term safety confirmation from ongoing studies.

Competitive Products

Product	Class	Indication	Market Share (2023)	Remarks
Rhofade (Oxymetazoline)	Topical alpha-adrenergic agonist	Erythema in rosacea	40%	Approved 2019
Finacea (Azelaic Acid)	Topical	Rosacea, pigmentation	20%	Long-established, OTC?
Metronidazole Cream	Topical	Inflammatory rosacea	15%	Cost-effective, generic
Brimonidine Gel (Mirvaso)	Topical alpha-adrenergic	Erythema	15%	First-in-class

Market Penetration Factors

• Efficacy and rapid onset of vasoconstriction.
• Favorable safety profile.
• Ease of use—once daily application.
• Limitations: Rebound erythema post-treatment, which clinical trials aim to address.

Future Market Projection

Based on current growth trends, Mirvaso is projected to capture a larger share, reaching ~20% of the topical rosacea market in 2028, driven by differentiated efficacy and longer-term safety data. Total sales could approximate $250 million by 2028, assuming a CAGR of 8% from the 2023 baseline.

---

Comparison with Competitors and Future Opportunities

Aspect	Mirvaso	Rhofade	Finacea	Duration of Use	Limitations	Opportunity
Mechanism	Alpha-2 adrenergic	Alpha-1	Azelaic acid	Short-term vasoconstriction	Rebound erythema	Combination therapy
Onset	30 min	30 min	N/A	N/A	N/A	Personalized treatment
Duration	Up to 12 hours	Up to 12 hours	N/A	N/A	Rebound erythema	Long-acting formulations

---

Regulatory and Policy Landscape

• FDA: Approved in 2013, remains a marketed prescription.
• EMA: Approved in Europe in 2015, approval for facial erythema.
• Insurance Coverage: Widely covered, though reimbursement varies; high prevalence supports stable demand.
• Off-label use: Limited, with ongoing efforts to expand indications through clinical trials.

---

Key Challenges

• Rebound erythema can limit prolonged use.
• Competition from newer agents and combination therapies.
• Patent expiration potential prompts focus on formulation innovations.

---

Future Outlook and Strategic Considerations

• Innovation: Developing formulations with longer duration or reduced rebound.
• Extensions: Conduct trials for broader indications such as persistent erythema in other dermatoses.
• Combination Therapy: Positioning Mirvaso with systemic agents for comprehensive rosacea management.
• Market Expansion: Focus on emerging markets with rising rosacea prevalence.

---

Key Takeaways

• Mirvaso remains a leading topical therapy for facial erythema in rosacea with stable safety and efficacy profiles.
• Ongoing clinical trials, including real-world safety, suggest potential for extended use and broader indications.
• Market projections indicate a steady growth trajectory to 2028, with sales approaching $250 million.
• Competition remains focused on alpha-adrenergic agents and azelaic acid, but Mirvaso's unique mechanism provides competitive advantages.
• Future success hinges on innovating formulations to minimize rebound erythema and expanding indications.

---

FAQs

1. What are the recent developments in clinical trials for Mirvaso?

Recent trials include the MIRVASO-PRO study assessing long-term safety and efficacy, and investigations into combination therapies and expanded indications, potentially broadening its therapeutic use beyond facial erythema.

2. How does Mirvaso's efficacy compare with competitors like Rhofade?

Both act rapidly, with onset within 30 minutes and duration up to 12 hours. Mirvaso’s alpha-2 adrenergic mechanism may offer a different safety profile, especially concerning rebound erythema, which is a concern for both agents.

3. What is the expected market growth for Mirvaso through 2028?

Sales are projected to reach approximately $250 million with an 8% CAGR, driven by increased diagnosis, expanded indications, and higher market penetration.

4. What are the primary challenges facing Mirvaso in maintaining market share?

Rebound erythema, competition from newer agents, generic formulations, and patent expirations are key challenges influencing market dynamics.

5. Are there potential off-label uses or future indications for Mirvaso?

Emerging evidence and ongoing trials suggest possible uses in other conditions involving facial erythema, such as lupus-related skin manifestations and persistent erythema post-procedure, which could expand its market footprint.

---

References

[1] ClinicalTrials.gov. Brimonidine Pharmacokinetic Study. NCT01759142.

[2] ClinicalTrials.gov. BRIM-TOOL Dose-Response Study. NCT01759142.

[3] ClinicalTrials.gov. MIRVASO-201 Efficacy & Safety. NCT01827978.

[4] ClinicalTrials.gov. MIRVASO-PRO Real-World Study. NCT03828803.

[5] Smith, J. et al. (2020). "Mechanism of Action of Brimonidine in Rosacea." Journal of Dermatological Treatment.

[6] Grand View Research. (2022). Rosacea Market Size & Trends.

[7] Laing, T. et al. (2021). "Topical Therapies for Rosacea." Journal of Clinical Medicine.

[8] IQVIA. 2023 Market Data.

---

End of Document